Peer-reviewed veterinary case report
Stem cell kidney treatment tested in cats with chronic kidney disease
By Thomson, Abigail L et al.·Published in Journal of veterinary internal medicine·2019·The Animal Medical Center, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Intra-arterial renal infusion of autologous mesenchymal stem cells for treatment of chronic kidney disease in cats: Phase I clinical trial.
- Species:
- cat
Plain-English summary
Five cats with chronic kidney disease (CKD) were treated with a new method involving the infusion of their own stem cells directly into the renal artery. This approach was tested to see if it could improve kidney function, as traditional treatments have not been effective. The procedure was successfully completed without any serious side effects, and the cats were monitored for three months. While the treatment was safe and feasible, its effectiveness in improving kidney function still needs further investigation.
People also search for: cat chronic kidney disease treatment · stem cell therapy for cats · improving cat kidney function · cat kidney disease symptoms · safe treatments for cat CKD
Abstract
BACKGROUND: There are no known treatments that halt or reverse chronic kidney disease (CKD) in cats. In rodent models, stem cell treatment has been associated with improvement in renal function parameters, especially when stem cells were delivered intra-arterially to the kidney. To date, only IV and intrarenal stem cell infusions have been studied in cats with CKD with no clinically relevant improvement noted. OBJECTIVE: To assess the safety and feasibility of intra-arterial delivery of autologous mesenchymal stem cells (MSC) in stromal vascular fraction (SVF) to the kidney in cats with CKD. ANIMALS: Five client-owned domestic cats with International Renal Interest Society stage III CKD. METHODS: Prospective cohort study (phase I clinical trial). Adipose tissue was harvested from study animals on day 0. On days 2 and 14, an infusion of MSC in SVF was administered into the renal artery via the femoral or carotid artery using fluoroscopic guidance. Serum creatinine and blood urea nitrogen concentration, plasma iohexol clearance, and quality of life assessments were monitored between days 0 and 90. RESULTS: The procedure was performed successfully in all cats. No severe adverse events were observed in any cat during the study period. CONCLUSIONS AND CLINICAL IMPORTANCE: Intra-arterial infusion of MSC into the renal artery in CKD cats was feasible and safe within a 3-month postoperative period. Efficacy and long-term safety have yet to be established. This procedure requires careful technique and training.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30924554/